Stock Ratings / Health Care / NPCE / forecast

CARL (39) SI (42) SSII (39) OFIX (55) ⌘ Pro Terminal →

Neuropace Inc. (NPCE) 12-Month Stock Forecast & Price Target Cone

$13.01 +0.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.00

Neuropace Inc. (NPCE) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $446.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.00 (-0.08%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NPCE)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY NPCE SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (30% of score)

20D Institutional Volume Accumulation (±9.6% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 37% of 52W Range • RSI-14 at 39.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.67-3.4% Next Q

Q2 (-2Q)

Grade E$12.24+5.5% Next Q

Q3 (-1Q)

Grade E$12.91+0.8% Next Q

Current

Grade E$13.01-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NPCE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NPCE currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.68) and Max Pain ($13.66) forces dealer call-delta covering toward $20.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NPCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NPCE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NPCE Position Size: $10,000

Shares at $13.01: 768.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $8.87

$6,818

$-3,182 (-31.8%)

12M Consensus BaseTarget $11.37

$8,739

$-1,261 (-12.6%)

12M Bull Case BreakoutTarget $20.58

$15,819

+$5,819 (+58.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$12	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$19	69%	B
JP MorganUS Large-Cap Research	SELL	$10	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NPCE)

✓Walkthrough of NPCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NPCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.84%⚡ TESTING RESISTANCE

2026-10-30O $13.01H $13.10L $12.25C $13.01VOL 80.9K

RES: $13.27SUP: $11.77SMA50: $13.68SMA200: $14.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NPCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NPCE Butterfly Map → + Track NPCE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NPCE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NPCE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NPCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NPCE)

Health Care Rank #941 of 1016 ⚔️ CARL vs NPCE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NPCE vs. CARL, SI, SSII, OFIX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuropace Inc. (NPCE) ranks #941 by composite RQD confidence (30/100, grade E) and #467 by equity capitalization ($446.6M). Within this direct 5-issuer industry benchmark cohort, NPCE leads on earnings valuation at N/A trailing P/E, while OFIX leads on capital efficiency and profitability with -12.2% ROIC and 68.8% gross margin. OFIX currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with NPCE at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NPCE ACTIVE Neuropace Inc.	E	30/100	—	77.2%	-23.0%	+0.62%	$446.6M	Benchmark Subject
CARL Carlsmed Inc.	D-	39/100	—	75.3%	-35.0%	+3.01%	$430.6M	/carl-vs-npce →
SI Shoulder Innovations Inc.	D-	42/100	—	76.5%	-16.1%	+4.93%	$425.5M	/si-vs-npce →
SSII SS Innovations International Inc.	D-	39/100	—	46.0%	-18.5%	-2.46%	$477.2M	/ssii-vs-npce →
OFIX Orthofix Medical Inc.	D+	55/100	—	68.8%	-12.2%	+1.99%	$417.1M	/ofix-vs-npce →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001528287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuropace Inc. (NPCE) reported GAAP revenue of $100.0M (+25.1% vs. FY2024 revenue of $79.9M , and +52.8% cumulative change since FY2023) , GAAP net income of -$21.5M, operating cash flow of -$11.0M, and free cash flow of -$11.3M (+37.9% YoY). On the balance sheet, NPCE closed FY2025 with $105.6M in total assets against $58.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$100.0M	-$21.5M	-$11.0M	-$11.3M	$105.6M	$58.9M
FY2024 (FY)	2024-12-31	$79.9M	-$27.1M	-$17.9M	-$18.3M	$94.6M	$59.5M
FY2023 (FY)	2023-12-31	$65.4M	-$33.0M	-$19.7M	-$19.7M	—	—

3. NPCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.01 (+0.62% 1D, market cap $446.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NPCE ranks #941 in composite RQD confidence.

How does NPCE compare to CARL and SI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $430.6M) and SI (Shoulder Innovations Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -16.1%, cap $425.5M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while OFIX leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NPCE?

Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NPCE trading relative to its 50-day, 200-day, and 52-week technical levels?

NPCE last traded at $13.01 (+0.62% on volume of 104,579 shares), positioning the stock -4.90% below its 50-day simple moving average ($13.68) and -13.15% below its 200-day simple moving average ($14.98). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 36.5% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($11.76 to $14.26).

NPCE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NPCE's 12-month stock price target?

Neuropace Inc. (NPCE) carries a 12-month consensus base price target of $11.37 (-12.6% from $13.01), with a bull-case target of $20.58 and a bear-case floor of $8.87.

Is NPCE stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NPCE E (Strong Sell — SELL) with an RQD Confidence score of 30/100.

Direct Sub-Reports: NPCE RQD Cockpit NPCE 12M Forecast NPCE Earnings & Move NPCE Dividends & DRIP NPCE Insiders & 13F NPCE Whale Options NPCE Profit Sankey NPCE News & Why